Lestaurtinib

Drug Profile

Lestaurtinib

Alternative Names: CEP-701; KT 5555; SPM 924

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Kyowa Hakko
  • Developer Cephalon; Children's Oncology Group; Icahn School of Medicine at Mount Sinai; Kyowa Hakko; National Cancer Institute (USA); Teva Pharmaceutical Industries
  • Class Antineoplastics; Carbazoles; Indoles; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute lymphoblastic leukaemia
  • Phase II Acute myeloid leukaemia; Myelofibrosis; Polycythaemia vera; Thrombocytosis
  • Discontinued Multiple myeloma; Pancreatic cancer; Plaque psoriasis; Prostate cancer

Most Recent Events

  • 04 Sep 2015 Phase-II development for Acute myeloid leukaemia (Second-line therapy or greater, Combination therapy), Myelofibrosis, Polycythaemia vera and Thrombocytosis is ongoing in USA
  • 04 Sep 2015 No recent reports on development identified - Phase-II for Acute myeloid leukaemia (Second-line therapy or greater) in Ukraine, Sweden, Spain, Australia, Canada, Germany, Israel, Italy, New Zealand, Poland, Romania and Russia (PO)
  • 24 Jun 2009 Discontinued - Phase-I for Prostate cancer in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top